INHIBITORS OF PEPTIDYLARGININE DEIMINASES

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compoun...

Full description

Saved in:
Bibliographic Details
Main Authors Hansen, Timothy R, Canales, Eda Y, Pyun, Hyung-Jung, Huang, Richard, Saito, Roland D, Cai, Zhenhong R, Debien, Laurent P, Loyer-Drew, Jennifer A, McFadden, Ryan, Byun, Daniel H, Xu, Lianhong, Van Veldhuizen, Joshua J, Mitchell, Michael L, Jansa, Petr, Sangi, Michael S, Taylor, James G, Schrier, Adam J, Shatskikh, Marina E, Lee, Rick A
Format Patent
LanguageEnglish
Published 23.03.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
Bibliography:Application Number: US202117557860